nntp2http.com
Posting
Suche
Optionen
Hilfe & Kontakt

Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients

Von: pautrey (rpautrey2@gmail.com) [Profil]
Datum: 03.06.2010 20:24
Message-ID: <083b8b08-e314-4ba8-9116-803174dfa457@a30g2000yqn.googlegroups.com>
Newsgroup: alt.healthmisc.kids.health
Volume 26, Issue 4, Pages 450-459 (August 2007)


Design of a multispecies probiotic mixture to prevent infectious
complications in critically ill patients

Harro M. Timmermanabc, Laetitia E.M. Niersd, Ben U. Ridwane, Catherina
J.M. Koningcf, Linda Mulderc, Louis M.A. Akkermansa, Frans M.
Romboutsg, Ger T. Rijkersbh


Received 17 October 2006; accepted 19 April 2007.

Summary
Background & aims
Although the potential for probiotics is investigated in an increasing
variety of diseases, there is little or no consensus regarding the
desired probiotic properties for a particular disease in question, nor
about the final design of the probiotic. Specific strain selection
procedures were undertaken to design a disease-specific multispecies
probiotic.

Methods
From a strain collection of 69 different lactic acid bacteria a
primary selection was made of 14 strains belonging to different
species showing superior survival in a simulated gastrointestinal
environment. Functional tests like antimicrobial activity against a
range of clinical isolates and cytokine inducing capacity in cultured
human peripheral blood mononuclear cells were used to further identify
potential strains.

Results
Specific strains inhibited growth of clinical isolates whereas others
superiorly induced the anti-inflammatory cytokine IL-10. Based on
functional tests and general criteria regarding probiotic design and
safety, a selection of the following six strains was made (Ecologic
641); Bifidobacterium bifidum, Bifidobacterium infantis, Lactobacillus
acidophilus, Lactobacillus casei, Lactobacillus salivarius and
Lactococcus lactis. Combination of these strains resulted in a wider
antimicrobial spectrum, superior induction of IL-10 and silencing of
pro-inflammatory cytokines as compared to the individual components.

Conclusions
Application of strict criteria during the design of a disease-specific
probiotic prior to implementation in clinical trials may provide a
rational basis for use of probiotics.

Keywords: Disease-specific probiotic, Multispecies probiotic,
Bifidobacterium, Lactobacillus, Lactococcus, Critically ill patients,
Small bowel bacterial overgrowth, Mucosal barrier, Immune system,
Bacterial translocation, Infection
Abbreviations: CFU, colony-forming units, CNS, coagulase-negative
Staphylococcus, LAB, lactic acid bacteria, MRS, de Man, Rogosa and
Sharpe, PBMC, peripheral blood mononuclear cell, PHA,
phytohaemagglutinin, SBBO, small bowel bacterial overgrowth, TLR, toll-
like receptor
a Department of Surgery G04 228, University Medical Center Utrecht, PO
Box 85500, 3508 GA, Utrecht, The Netherlands

b Laboratory of Pediatric Immunology, Wilhelmina Children's Hospital,
University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The
Netherlands

c Winclove Bio Industries B.V., P.O. Box 37239, 1030 AE Amsterdam, The
Netherlands

d Department of Pediatric Immunology, Wilhelmina Children's Hospital,
University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The
Netherlands

e Department of Medical Microbiology, University Medical Center
Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands

f Departments of Gastroenterology and Medical Microbiology, University
Maastricht, P. Debeyelaan 25, 6202 AZ Maastricht, The Netherlands

g Laboratory of Food Microbiology, Department of Agrotechnology and
Food Sciences, Wageningen University, P.O. Box 8129, 6700 EV
Wageningen, The Netherlands

h Department of Medical Microbiology and Immunology, St. Antonius
Hospital, PO Box 2500, 3430 EM Nieuwegein, The Netherlands

Corresponding author. Department of Surgery G04 228, University
Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, The
Netherlands. Tel.: +31302506489; fax: +31302541944.

PII: S0261-5614(07)00072-6

doi:10.1016/j.clnu.2007.04.008

© 2007 Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. All rights reserved.

Read More:
http://www.journals.elsevierhealth.com/periodicals/yclnu/article/S0261-5614
(07)00072-6/abstract

[ Auf dieses Posting antworten ]